Daiichi’s Japan Filing The First For Denosumab In RA
Executive Summary
Daiichi Sankyo has filed for the approval in Japan of denosumab for rheumatoid arthritis, marking the first such filing for the Amgen-originated antibody in this setting.
You may also be interested in...
Japan Rebound For Amgen With Daiichi Biosimilars Deal
A few weeks after its R&D alliance in Japan with Takeda was scaled back, Amgen has found a new partner in the country, this time for the commercialization of a broad portfolio of biosimilars.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: another big deal in radiopharmaceuticals; BioNTech’s ADC pipeline; China CDMOs embrace uncertain future; at look at the rivals in MASH; and industry views on how AI might be transformative.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Galderma prepares to take on Dupixent; Pfizer’s plans for Adcetris in DLBCL; Lilly’s donanemab approval delayed again; the psychedelic R&D pipeline; and an interview with BMS’s CDTO Greg Meyers.